Therapeutic Antibodies

Guest Editor:

Dr. Alastair Lawson
Structural Biology, UCB, 216 Bath Road, Slough SL1 3WE, UK

Deadline for manuscript submissions:
closed (31 October 2017)

Message from the Guest Editor

Dear Colleagues,

Over the last thirty years, therapeutic antibodies have gone from “not existing” to being the world’s top prescription drugs, largely through their ability to bring protein-protein interactions into play in medicine. This Special Issue of *Antibodies* charts the rise of therapeutic antibodies and acknowledges the technological hurdles that have been overcome to make them front line therapies. In addition, we will address the limitations of such products, such as potential immunogenicity, supply chain complexity and cost of treatment. Finally the Special Issue will cover alternative therapeutic modalities, which represent potential disruptive technologies for antibodies in the future.

Dr. Alastair Lawson
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. Arne Skerra
Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: CiteScore - Q1 (*Drug Discovery*)

Contact Us